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1. Introduction
The human gut microbiota is of major importance 
in metabolic and physiological processes (Vyas and 
Ragnanathan, 2012). Additionally, the microbiota is 
proposed to play a key role in development, maturation and 
maintenance of the immune system (Alonso and Guarner, 
2013; Buccigrossi et al., 2013; Kamada et al., 2013). Indeed, 
when individuals fail to acquire a ‘normal’ microbiota 
it is associated with illnesses and other complications 
(Buccigrossi et al., 2013; Hickey et al., 2012). For instance, 
the increasing prevalence of allergies in the developed world 
could be partially explained by the ‘hygiene hypothesis’ 
(Strachan, 1989). This hypothesis postulates that improved 
hygiene, healthcare and smaller families leads to a decrease 
in antigen exposure, including bacteria and fungi, thereby 
affecting immune development of infants and children (Van 
der Aa et al., 2010). The lack of bacterial exposure skews the 
immune response to a more IgE-mediated TH2-response, 
which is associated with allergies and other pathologies. 
The early microbial colonisation is not only important 
in polarising the appropriate TH1/TH2 balance; it is also 
suggested to play a role in regulatory mechanisms (Pan et 
al., 2010). This colonisation by microorganisms recognised 
as harmless by the immune system, also called ‘old friends’, 
drive regulatory T-cell polarisation and thereby down 
regulate auto- and allergic-immune responses (Guarner 
et al., 2006). Indeed, insufficient exposure to these ‘old 
friends’ might lead to a dysfunctional immune regulation. 
For instance, the risk of asthma is inversely related to the 
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Abstract
This study aimed to systematically evaluate safety of probiotics and synbiotics in children ageing 0-18 years. This 
study is the third and final part in a safety trilogy and an update is provided using the most recent available clinical 
data (2008-2013) by means of the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification. 
Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, 
dosage, clinical condition and selected afflictions. Analysis of 74 clinical studies indicated that probiotic and/or 
synbiotic administration in children is safe with regard to the specific evaluated strains, dosages and duration. The 
population of children include healthy, immune compromised and obese subjects, as well as subjects with intestinal 
disorders, infections and inflammatory disorders. This study revealed no major safety concerns, as the adverse 
events (AEs) were unrelated, or not suspected to be related, to the probiotic or synbiotic product. In general the 
study products were well tolerated. Overall, AEs occurred more frequent in the control arm compared to children 
receiving probiotics and/or synbiotics. Furthermore, the results indicate inadequate reporting and classification of 
AEs in the majority of the studies. In addition, generalizability of conclusions are greatly limited by the inconsistent, 
imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration 
regimes, study populations and reported outcomes.
Keywords: probiotics, synbiotics, children, safety, prebiotics
ht
tp
://
w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
14
.0
15
7 
- F
rid
ay
, F
eb
ru
ar
y 
16
, 2
01
8 
6:
54
:1
1 
A
M
 - 
IP
 A
dd
re
ss
:1
45
.5
.8
7.
23
3 
M. van den Nieuwboer et al.
616 Beneficial Microbes 6(5)
variety of microbial exposure (Ege et al., 2011). Children 
living in rural areas had a lower prevalence of asthma and 
atopy compared to children living in suburban areas (Ege 
et al., 2011). In addition to the autoimmune regulation, 
a shift from TH1 to TH2 cells renders individuals more 
susceptible to infections (Tan et al., 2011).
A possible therapeutic measure to modulate the aberrant 
gut composition is by supplementation of probiotics. 
Probiotics are defined as ‘live microorganisms that, 
when administered in adequate amounts, confer a health 
beneﬁt on the host’ (Hill et al., 2014). Probiotics are often 
supplemented with prebiotics, which are ‘non-viable 
food components that confer a health benefit on the host 
associated with modulation of the microbiota’ (Piniero et 
al., 2008). Probiotics and prebiotics combined are defined 
as synbiotics. Although some mechanism of probiotics are 
widespread among genera, most beneficial health effects of 
probiotics are strain-specific and cannot be extrapolated to 
other probiotics (Hill et al., 2014). Currently, there is still 
discussion regarding the efficacy of probiotics, as studies 
report contrasting results. Selection of the proper single 
or multi-strain probiotic strain is crucial for efficacy in 
various illnesses. In addition, administration of varying 
dosages with deviating interventional periods contribute 
to inconclusive results (Sanders et al., 2013).
Despite the concerns regarding the contrasting efficacy data, 
promising results have been reported in various disease areas 
in children and infants (Weichert et al., 2012). Probiotic 
supplementation to children seems to prevent respiratory 
tract infections. A Cochrane review of well-designed 
randomised controlled trials (RCT) demonstrated that the 
incidence of upper respiratory tract infections (URTI) was 
lower in the probiotic group compared to the placebo (Hao 
et al., 2011). Administration of Lactobacillus rhamnosus 
GG demonstrated a lower incidence of recurrent URTIs in 
children ageing 1-6 years (odds ratio = 0.56; 95% confidence 
interval: 0.31-0.99) (Hatakka et al., 2007). Additionally, there 
is accumulating evidence that probiotics are beneficial in 
the treatment of acute diarrhoea; in both duration as well 
as stool frequency (Allen et al., 2010). For instance, a meta-
analysis evaluating the effect of Saccharomyces boulardii 
demonstrated a reduction of diarrhoea duration by one day 
(Szajewska and Skórka, 2009).
2. Safety
Although most probiotic strains are designated as GRAS 
(generally recognised as safe) by the United States Food and 
Drug Administration (FDA), there remain certain concerns 
regarding potential safety issues. For instance, probiotic 
bacteria can become opportunistic and translocate through 
the gastrointestinal barrier, might be toxic, have adverse 
immunologic effects or can potentially spread antibiotic 
resistance to pathogenic species (Klein, 2011).
Probiotic and synbiotic safety in children, particularly when 
immune compromised, remains unclear. These individuals 
have a defective microbial clearance and are thereby more 
susceptible to opportunistic bacteria (Boyle et al., 2006). An 
extensive exploratory safety analysis of probiotics by Hempel 
et al. (2011) indicated, however, that probiotics are safe. 
Additionally, a previous report by Van den Nieuwboer et al. 
(2014) concluded that there was no increased health risk in 
infants less than two years of age. As this study only focussed 
specific on participants under 24 months old, an overview of 
the safety data for infants and children older than 24 months 
is still lacking. Therefore, this reports aims to review the 
safety data of probiotic and synbiotic interventions focusing 
on the child population ageing 0 to 18 years old. In specific, 
it will provide an update with the most recent intervention 
studies on the previous safety analysis by Hempel et al. 
(2011). This analysis will provide a clear overview of any 
safety concerns for high-dosage and chronic probiotic use 
in at-risk child populations, by taking health conditions, 
probiotic intake and study duration into account.
3. Methodology
In order to analyse the safety of probiotics and synbiotics 
in children an extensive literature study was conducted. 
Clinical studies were retrieved from the online database 
PubMed (National Library of Medicine, includes 
MEDLINE). Eligible articles were retrieved using the 
search terms ‘probiotics’ or ‘synbiotics’ in combination with 
‘children’, ‘kids’ and ‘adolescents’. This search strategy was 
complemented with filters to solely include human studies 
published within the last five years (2008-2013), thereby 
excluding all animal and in vitro studies. All studies were 
subsequently reviewed for clinical phase and status using 
clinical trials registry databases clinicaltrials.gov and isrctn.
org. Articles were considered eligible if the investigators 
conducted an interventional study using a probiotic, a 
mixture of probiotics or synbiotics in children ageing 
between 0 and 18 years. All original and follow-up studies 
were included, without probiotic species or study design 
restrictions (both pilot studies as well as double blinded, 
randomised, placebo controlled studies were included). 
Both mechanistic studies as well as studies attempting to 
cure, treat, alleviate or prevent an illness were incorporated 
into this analysis. A total volume of 259 studies describing 
a probiotic or synbiotic intervention in participants 
aging from birth to 18 years were analysed according to 
their respective abstract and title for applicability and, 
subsequently, a full text analysis was conducted. Studies 
including a specific participant population concerning 
very young infants ageing between 0 and 24 months were 
excluded (n=73; these data are described in Van den 
Nieuwboer et al., 2014). An additional 113 articles were 
excluded as no probiotic intervention was conducted during 
the study or did not meet the inclusion criteria. Finally, the 
safety data were analysed for 74 studies (Torii et al., 2011 
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and Boonyaritichaikij et al., 2009 described two studies 
in one paper), of which all were original studies (Table 1).
The safety profile of the administered probiotics and 
synbiotics were assessed by means of the reported adverse 
events (AEs), and analysed according to their nature and 
quantity. AEs are defined as the occurrence of complications 
or illnesses, or worsening of the condition throughout the 
study. The adverse events were categorised according to 
the Common Terminology Criteria for Adverse Events 
(CTCAE version 4.0, NIH, 2009) classification system 
(Table 2). The CTCAE divides the AEs into 26 categories 
and grades according to the severity. This study did not grade 
the severity of the AEs as this data was missing or difficult 
to interpret. An extra category ‘unspecified’ was added, 
since not all reported AEs could be properly categorised. 
Furthermore, this review did not distinguish between 
relatedness and seriousness of the AEs, as this depends on 
judgement of the investigators, and overall meta-analyses.
Other relevant data, such as probiotic strains, dosage and 
intervention duration were taken into account for analysis 
of the intervention. Beneficial effects of probiotics are 
mainly strain specific, therefore it is essential to determine 
which strains have been tested at high-dosage and chronic 
use compared to their respective safety profile. This study 
was not designed to sufficiently evaluate the efficacy. It 
should be noted that this review uses the terms probiotics 
and synbiotics interchangeably, as the synbiotics contain 
probiotic strains.
4. Results
In the eligible 74 studies, a total of 15,885 participants were 
randomly allocated to the treatment and control arms. In 
the treatment arm, 8,472 participants were subjected to 
a probiotic and/or synbiotic treatment, with a drop-out 
rate of 7.96%, resulting in a per-protocol population of 
7.798 participants. In the control arm, 7,413 and 6,754 
participants were allocated and analysed per-protocol 
respectively, corresponding with a drop-out rate of 8.89%. 
Because some participants discontinued the study due to 
experienced AEs, all AEs in the allocated population were 
assessed to determine the safety profile. The majority of the 
studies were published between 2010 and 2011, whereas 
only two and six studies were published in 2013 and 2008 
respectively. The median duration of the clinical studies 
was 37 days (range: 3-635), with an exposure equal or less 
than 3 months in 62 (~84%) interventions. Only five studies 
evaluated chronic exposure of probiotics by administration 
of equal or more than one year (Figure 1 illustrates the 
study durations in days). The identified subgroups of 
participants were: (1) healthy children; (2) children with 
an intestinal disorder; (3) children with an inflammatory 
disorder or allergy; (4) children with an infection; (5) 
immune compromised children; and (6) obese children.
The study population was considerably heterogeneous, as 
the participants' age ranged from 0 to 18 years. For instance, 
where some studies solely included infants between 0 and 
48 months (El-Sawaf et al., 2013), other studies included 
Table 1. Evaluated studies.
Augustina et al., 2012 Hojsak et al., 2010a,b Sazawal et al., 2010
Aminabadi et al., 2011 Hurduc et al., 2009 Sentongo et al., 2008
Boonyaritichaikij et al., 2009 Kerac et al., 2009 Shafiei et al., 2011
Cazzola et al., 2010 Kumar et al., 2013 Simakachorn et al., 2011
Chen et al., 2010a,b Leyer et al., 2009 Singh et al., 2011
Cildir et al., 2009 Lin et al., 2013, 2009 Skovbjerg et al., 2009
Corrêa et al., 2011 Lue et al., 2012 Stecksén-Blicks et al., 2009
Dalgic et al., 2011 Martínez Cañavate et al., 2009 Sur et al., 2011
Dinleyici et al., 2009, 2011 Matsuda et al., 2011 Surono et al., 2011
El-Sawaf et al., 2013 Merenstein et al., 2010, 2009 Szachta et al., 2011
Eren et al., 2010 Miele et al., 2009 Szajewska et al., 2009
Fang et al., 2009 Miniello et al., 2010 Szymański et al., 2008
Francavilla et al., 2012, 2010 Misra et al., 2009 Tabbers et al., 2011
Gerasimov et al., 2010 Narayanappa et al., 2008 Tolone et al., 2012
Glavina et al., 2012 Nixon et al., 2012 Torii et al., 2011
Gøbel et al., 2012 Oliva et al., 2012 Vajro et al., 2011
Gotteland et al., 2008 Ouwehand et al., 2009 Vandenplas and De Hert, 2011
Guandalini et al., 2010 Passariello et al., 2012 Wada et al, 2010
Guerra et al., 2011 Pérez et al., 2010 Wanke and Szajewska, 2012
Han et al., 2012 Rerksuppaphol and Rerksuppaphol, 2010, 2012 Woo et al., 2010
Henker et al., 2008 Riaz et al., 2012 Wu et al., 2012
Heydarian et al., 2010 Ruszczyński et al., 2008
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children between one and 17 years (Miele et al., 2009). 
Figure 2 depicts the age range of eligible participants for 
each study.
5. Intervention
When focussing on the applied intervention in the 
treatment arm, 47.3% of the study products were non-
commercial whereas 52.6% were commercially available. 
The study product was most often applied as a single 
probiotic formulation (59.7%), followed by a probiotic 
mixture, consisting of two or more probiotic strains 
(28.5%). Synbiotic formulations were less common, 
as 5.2% of the study products concerned a single 
synbiotic product, consisting of one probiotic species in 
combination with prebiotics and 6.5% of the formulations 
concerned a synbiotic mixture consisting of two or more 
probiotic species in combination with prebiotics. The 
specific strain designation was lacking in 42% of the 
supplemented probiotics. The probiotic genus, species 
and strain was lacking in one study (Shafiei et al., 2011) 
and one study administered the questionable unknown 
strain Saccharomyces thermophilus (Kumar et al., 2013), 
demonstrating the poor quality of intervention reporting.
In total 84 different probiotic strains were supplemented in 
the interventions, with the majority of participants receiving 
Lactobacillus casei Shirota (n=1,893). This large population 
can be attributed to a single study by Sur et al. (2011), 
evaluating whether L. casei Shirota has a beneficial role 
in protecting children (1-5 year) from acute diarrhoea 
in an urban slum community. The second most frequent 
administered probiotic strain was L. rhamnosus GG 
(n=964). The bacterial species Streptococcus thermophilus, 
L. rhamnosus, Lactobacillus acidophilus, Bifidobacterium 
longum, Bifidobacterium bifidum, Bifidobacterium 
infantis, Lactobacillus plantarum (all lacking a specific 
strain designation) and the yeast S. boulardii were all 
administered to 400-900 participants each. Between 250 
and 400 participants received each Pediococcus pentosaceus 
16:1 LMG P-20608, Leuconostoc mesenteroides 23-
77:1 LMG P-20607, L. plantarum 2362 LMG P-20606, 
Lactobacillus paracasei F-19 LMG P-17806, L. casei DN-114 
001, Bifidobacterium lactis HN019, Lactobacillus gasseri 
OLL2716 and the unspecified species Lactobacillus brevis, 
Lactobacillus salivarius, Lactobacillus helviticus, L. casei and 
Enterococcus faecum. L. acidophilus NCFM, L. rhamnosus 
T cell-1, Lactobacillus reuteri DSM17938, L. casei CRL431, 
Clostridium butyricum TO-A, Bacillus mesentericus TO-
A, Bifidobacterium breve (unspecified), L. rhamnosus 
LB21, Enterococcus faecalis T-110, Lactobacillus johnsonii 
La1, L. salivarius PM-A0006, L. rhamnosus PEN (2593), 
L. rhamnosus Oxy (2595), L. rhamnosus E/N (2594), B. lactis 
Bi-07, L. paracasei (unspecified) and B. lactis DN-173010 
were all supplemented to 100-250 participants. The 
remaining 45 probiotic strains were supplemented to less 
than 100 participants, making the respective safety data 
less reliable. The allocated participants for each strain are 
illustrated in Figure 3.
Days
7006005004003002001000
St
ud
ies
 (n
)
10
8
6
4
2
0
Figure 1. Study duration of each intervention in days.
Table 2. Common terminology clinical adverse events (version 
4.0).
Category Designation
Blood and lymphatic system disorders I
Cardiac disorders II
Congenital, familial and genetic disorders III
Ear and labyrinth disorders IV
Endocrine disorders V
Eye disorders VI
Gastrointestinal disorders VII
General disorders and administration site conditions VIII
Hepatobiliary disorders IX
Immune system disorders X
Infections and infestations XI
Injury, poisoning and procedural complications XII
Investigations XIII
Metabolism and nutrition disorders XIV
Musculoskeletal and connective tissue disorders XV
Neoplasms benign, malignant and unspecified (incl. 
cysts and polyps)
XVI
Nervous system disorders XVII
Pregnancy, puerperium and perinatal conditions XVIII
Psychiatric disorders XIX
Renal and urinary disorders XX
Reproductive system and breast disorders XXI
Respiratory, thoracic and mediastinal disorders XXII
Skin and subcutaneous tissue disorders XXIII
Social circumstances XXIV
Surgical and medical procedures XXV
Vascular disorders XXVI
Unspecified XXVII
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Analysis of the applied dosage in cfu for each strain is 
shown in Figure 3. The median supplemented dosage was 
2.4×109 cfu per day, ranging from the lowest dosage of B. 
mesentericus TO-A (3.0×106 cfu/day) to the highest dosage 
of 1.5×1011 cfu/day with L. acidophilus L-92. The daily 
administered dosage was lacking or insufficiently reported 
in 29% of all the applied probiotic species. Several probiotic 
strains were tested according to a large range of dosages, for 
instance, S. boulardii, L. reuteri ATCC 55730, L. rhamnosus 
GG, B. bifidum (unspecified), B. longum (unspecified) and 
L. acidophilus (unspecified). The other strains were tested 
at a low dosage, a narrow range, the administered daily cfu 
was not reported or were only evaluated at a single dosage. 
There was no information available on the supplemented 
dosage for the strains Lactococcus casei, Lactococcus 
cremoris CNCM I-1631, Lactococcus lactis (unspecified), 
Lactococcus diacetylactis, Lactococcus plantarum 
(unspecified), Lactococcus rhamnosus (unspecified), 
Leuconostoc cremoris (unspecified), Saccharomyces 
florentinus (unspecified), L. paracasei (unspecified), 
L. helveticus R0052 (I-1722), Lactobacillus coryniformis 
CECT5711, L. gasseri CECT5714, L. casei DN-114 001/
CNCM I-1518, L. acidophilus DDS-1, B. lactis UABLA-12, 
B. infantis R0033 (I-3424), B. bifidum R0071 (I-3425) and 
B. breve (unspecified).
Different afflictions require different probiotic properties 
for alleviation, mitigation, prevention or treatment. Figure 
4 demonstrates the applied cfu for each subgroup and 
Figure 5 illustrates the allocated and analysed participants 
for each subgroup for the treatment and control arm. 
When focussing on the specific subgroups, the median 
intervention duration for the healthy participants was 90 
days (range: 10-365). A total of 4,780 and 3,900 healthy 
participants were allocated to the treatment and control 
arm respectively in 19 (25.6%) studies. Children received 
on average 6.5×109 cfu per day (range: 1.9×107-4.0×1010), 
with L. casei Shirota distributed most frequently among 
the participants (n=1,893).
The subgroup of gastrointestinal disorders consisted of 
children with acute diarrhoea (≤7 days), gastroenteritis, 
rota viral diarrhoea, constipation (functional and chronic), 
ulcerative colitis, Hirschprung disease, irritable bowel 
syndrome, recurrent abdominal pain and short bowel 
syndrome. A total of 1,493 and 1,467 participants were 
allocated to the treatment and control arm respectively in 24 
(32.4%) studies. These children participated in interventions 
with a median duration of 10 days (range: 5-365) and 
received on average 3.12×109 (range: 3.0×106-1.0×1010) 
cfu/day. The majority in this subgroup received the yeast 
S. boulardii (n=435).
The subgroup inflammatory disorders and allergies were 
combined as these included the disorders atopic dermatitis, 
asthma, allergic rhinitis and pollen fever. In 13 (17.5%) 
St
ud
y
Age (Months; Average, range)
21620419218016815614413212010896847260483624120
Age (y)
120 1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18
Figure 2. Age range in months and years for each study. The figure illustrates the youngest, average and oldest participant age 
included in each study.
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studies 561 and 548 participants were allocated to the 
treatment and control arm respectively. The median 
interventional period was 72 days (range: 56-121), in which 
the majority received L. salivarius PM-A0006 (n=147). 
The children received on average 2.05×1010 cfu per day, 
ranging from the lowest applied dosage of 1.0×108 cfu to 
the highest dosage of 1.5×1011 cfu per day.
The subgroup of children with an infection consisted of 10 
(13.5%) studies and includes participants with a Helicobacter 
pylori infection, children colonised by vancomycin-
St
ra
ins
Lactobacillus acidophilus L-92
Lactobacillus rhamnosus T cell-1
Pediococcus pentosaceus 16:1 LMG P-20608
Leuconostoc mesenteroides 23-77:1 LMG P-20607
Lactobacillus plantarum 2362 LMG P-20606
Lactobacillus paracasei F-19 LMG P-17806
Bifidobacterium lactis DN- 173010
Lactobacillus sakei KCTC 10755BP
L. plantarum CJLP133
Lactobacillus johnsonii EM1
Lactobacillus casei "unspecified"
Lactobacillus salivarius Ls-33 ATCC SD5208
Lactobacillus brevis "unspecified"
L. plantarum "unspecified"
Bifidobacterium infantis "unspecified"
L. casei Shirota
B. lactis "unspecified"
Saccharomyces boulardii
Streptococcus thermophilus "unspecified"
L. acidophilus NCFM (ATCC 700396)
Lactobacillus reuterii ATCC 55730
Enterococcus faecium "uspecified"
B. lactis Bi-07 (ATCC PTA-4802),
L. rhamnosus GG
Bifidobacterium bifidum "unspecified"
Bifidobacterium longum "unspecified"
Lactobacillus helveticus "unspecified"
Lactobacillus gasseri PM-A0005
L. rhamnosus "unspecified"
B. lactis Bl-04 (ATCC SD5219)
L. salivarius "unspecified"
Bifidobacterium breve Yakult (BBG-01)
L. acidophilus "unspecified"
L. salivarius PM-A0006
Lactobacillus paracasei B21060
S. thermophilus CNCM I-1630
Lactobacillus bulgaricus CNCM I-1632
L. bulgaricus CNCM  I-1519
Streptococcus sanguinis 89a, NCIMB 40104
L. reuterii "unspecified"
Escherichia coli Nissle 1917
L. rhamnosus LB21
L. rhamnosus Pen (2593)
L. rhamnosus E/N (2594)
L. gasseri OLL2716 (LG21)
L. rhamnosus Oxy (2595)
L. Johnsonii La1
L. paracasei NCC 2461
L. plantarum PL02
L. rhamnosus KL53A
B. longum PL03
Lactobacillus sporogenes
L. rhamnosus 35
L. reuteri DSM17938
B. longum BB536
L. casei CRL431
Saccharomyces thermophilus "unspecified"
Enterococcus faecium IS-27526
Enterococcus faecalis T-110
L. acidophilus CRL730
Streptococcus faecalis T-110
L. acidophilus La-5
B. lactis Bb-12
Clostridium butyricum TO-A
Bacillus mesentericus TO-A
B. lactis HN019
Saccharomyces florentinus "unspecified"
Leuconostoc cremoris "unspecified"
Lactococcus rhamnosus "unspecified"
Lactococcus plantarum "unspecified"
Lactococcus diacetylactis "unspecified"
Lactococcus lactis "unspecified"
Lactococcus cremoris CNCM I-1631
Lactococcus casei "unspecified"
L. paracasei "unspecified"
L. helveticus R0052( I-1722)
L. gasseri CECT5714
Lactobacillus coryniformis CECT5711
L. casei DN-114 001/CNCM I-1518
L. acidophilus DDS-1
B. lactis UABLA-12
B. infantis R0033 ( I-3424)"
B. breve "unspecified
B. bifidum R0071 (I-3425)
cfu/day (average, range)
1×10111×10101×1091×1081×1071×106
Participants (n)
2,0001,50010005000
62
525
39
51
48
84
742
28
39
315
150
75
190
190
40
47
650
48
312
103
24
112
39
57
62
511
83
166
215
46
40
58
399
454
47
399
55
105
148
63
62
315
55
253
24
24
1.893
314
206
315
79
79
355
246
875
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Figure 3. Range of daily administered cfu for each probiotic strain, and the respective participants receiving the strain.
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resistant enterococci, participants infected by the amoeba 
Entamoeba histolytica, children with otitis media and 
children requiring antibiotic treatment. A total of 630 and 
502 participants were allocated to the treatment and control 
arm respectively. The median duration of the intervention 
was 12.5 days (range: 7-365), in which the participants 
received on average 2.38×109 cfu per day (range: 6.6×108-
1.2×1010 cfu). L. johnsonii La1 was administered most 
frequently in this subgroup (n=148).
The immune compromised subgroup included hospitalised 
and critical ill children, children requiring mechanical 
ventilation and enteral nutrition, suffering from severe 
malnutrition or children affected by malignancies. In 6 (8.1%) 
studies, a total of 970 and 959 participants were allocated to 
the treatment and control arm. The participants received 
an intervention for a median of 10.8 days (range: 7-56), 
with a mean daily cfu of 7.09×109 (range: 5.0×107-2.5×1010 
cfu/day). P. pentosaceus 16:1 LMG P-20608, L. mesenteroides 
Co
nd
itio
ns
Inflammatory disorders
and allergies
Obesity
Immune compromised
Healthy
Intestinal disorders
Infections
cfu/day (average, range)
1×10121×10111×10101×1091×1081×1071×106
Figure 4. Minimal, average and maximal applied dosage in cfu per day for each health condition.
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Figure 5. Frequency of allocated and analysed participants in the treatment and control arm for each health condition.
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23-77:1 LMG P-20607, L. paracasei F-19 LMG P-17806 and 
L. plantarum 2362 LMG P-20606 were administered to the 
majority in this subgroup (n=399).
Finally, the obese subgroup consisted of two studies 
(2.7%) with a median duration of 70 days (range: 56-84). 
Participants received on average 1.1×1010 cfu per day 
(range: 1.0×1010-1.2×1010 cfu/day). A total of 38 and 37 
participants were allocated to the treatment and control 
arm respectively, whereas the majority received L. salivarius 
Ls-33 ATCC SD5208 (n=28). Considering the above 
mentioned data, majority of the participants were healthy, 
and probiotics were tested for each condition according to 
a large range of dosages (except for obesity).
6. Safety
The 74 studies were analysed for their non-specific overall 
safety statement of the study product, regardless of the 
reported adverse events. As illustrated in Figure 6, the safety 
statement that ‘no AEs were reported during the intervention’ 
was most common (n=25) and the study product was ‘well 
tolerated’ in 13 studies. In seven interventional studies there 
was ‘no significant difference in AEs between study groups’, 
and six papers stated there was ‘no AE related to the study 
product’. One study (Hurduc et al., 2009) indicated that the 
intervention led to ‘reduced side effects’, whereas Agustina 
et al. (2012) stated there were ‘increased complications’. 
Strikingly, safety and AEs were not discussed in 21 (28.4%) 
studies; these studies did not address any AEs and risks of 
probiotic or synbiotic interventions.
By analysing the clinical data according to the CTCAE, a 
total of 3,418 and 3,879 AEs were identified in the treatment 
and the control arm respectively. Gastrointestinal disorders 
(category VII) occurred most frequently (n=5,470) followed 
by infections and infestations (category XI; n=884) and 
respiratory, thoracic and mediastinal disorders (category 
XXII; n=546). Figure 7A illustrates the distribution of all 
reported AEs across both intervention arms. The most 
common AEs were diarrhoea (VII), dysentery episodes 
(VII), URTIs (XI), rhinorrhoea (XXII) and cough (XXII). A 
total of 122 AEs were not properly specified and thus could 
not be categorised according to the CTCAE. This concerned 
44 AEs in the treatment arm and 78 AEs in the control 
arm. Except for general disorders and administration site 
conditions (category VIII; n=220), AEs in the other CTCAE 
categories did not occur, or in a relative low frequency.
Subgroup analysis indicated that a gastrointestinal disorder 
(VII) was the most common AE reported by healthy 
participants; 2,480 and 2,665 AEs in the treatment and 
control arm respectively (Figure 7B). AEs in the category 
respiratory, thoracic and mediastinal disorders (XXII) 
and infections and infestations(XI) occurred relatively 
frequent (n=544 and 540 respectively). Despite of two 
single events in the treatment group, an immune system 
disorder (X) and a surgical or medical procedure (XXV), 
the frequency of reported AEs in the treatment group was 
lower for each CTCAE category. Overall the incidence 
of AEs was lower in the group receiving probiotics or 
synbiotics compared to the control group, regardless 
of the 880 more participants that were allocated to this 
intervention group. Remarkable is the low frequency of 
reported AEs in the gastrointestinal disorder subgroup, 
with a total AE count of 50. In this relatively large group 
of participants (n=2,960), gastrointestinal disorders (VII) 
were most commonly observed (n=29), followed by 
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Figure 6. Overall non-specific safety statement of each study.
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Figure 7. Reported adverse events (AE) in the treatment and control arm. (A) Total AE in children; (B) AEs in healthy children; 
(C) AEs in children with an intestinal disorder; (D) AEs in children with an allergy or inflammatory disorder; (E) AEs in infected 
children; (F) AEs in immune compromised children.
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‘unspecified’ AEs (XXVII; n=10). The occurrence of AEs 
was higher in the control group in all CTCAE categories, 
except for two unrelated ‘injury, poisoning and procedural 
complications’ (XII) in the treatment group (Figure 7C). 
In the subgroup inflammatory disorders and allergies, 
infections and infestations (XI) occurred most frequently 
followed by gastrointestinal disorders (VII). Four more 
gastrointestinal AEs were reported in the treatment group, 
three diarrheal events and one abdominal colic event. 
Although of concern, the frequency of AEs in this group 
was relatively low (Figure 7D). Gastrointestinal disorders 
(VII) occurred most frequently in the subgroup of infected 
children, whereas the incidence was lower in the treatment 
group (n=33 vs 56 respectively). This was mainly due to 
a higher incidence of diarrhoeal episodes in the control 
group. The total frequency of AEs was 109, with 38 and 
71 AEs in the treatment and control arm respectively, 
whereas the number of AEs in the treatment group was 
lower for each CTCAE category (Figure 7E). In the immune 
compromised subgroup infections and infestations (XI) 
and gastrointestinal disorders (VII) were most often 
observed. This concerned episodes of sepsis and diarrhoea 
and vomiting (n=137, 125 and 72 respectively). No AEs of 
the other categories were reported and in both CTCAE 
categories (XI and VII) the frequency of AEs was lower in 
the treatment arm compared to the control arm (Figure 
7F). There were no AEs reported in the obesity group.
7. Conclusion and discussion
Analysis of the 74 interventional studies indicated that 
in the setting of a controlled clinical trial, probiotic and 
synbiotic administration in children between the age of 0 
and 18 years is not associated with an increased health risk. 
This statement is however limited to the supplemented 
strains and their respective dosage, exposure duration and 
target patient population. As probiotic properties are mainly 
strain-specific, both efficacy as well as safety data cannot 
be extrapolated to other probiotics of the same species, or 
probiotic organisms in general (Hill et al., 2014). This update 
is in line with previous analyses, indicating that probiotics 
are safe, even in infants and immune compromised adults 
(Hempel et al., 2011; Van den Nieuwboer et al., 2014, 2015).
Data indicate no significant difference between documented 
AEs in the treatment and control group (n=3,418 and 
3,879 respectively); for the total population as well as the 
specific patient populations. For each patient population, 
the incidence of AEs in each category was lower in the 
treatment group compared to the control group (except 
for two more AEs in the category gastrointestinal 
disorders (VII) in children inflammatory disorders and 
allergy; ns). The overall incidence rate of AEs was 0.40 
and 0.52 in the treatment and control arm respectively. 
The majority of the AEs in the ‘healthy’ subgroup, children 
receiving probiotics for disease prevention, were non-
serious of nature (diarrhoea, cough and URTIs) and often 
the frequency was lower in the probiotic group. Leyer 
et al. (2009) demonstrated a significant lower incidence 
of fever (VIII) and cough (XXII) after administration of 
L. acidophilus NCFM and a reduction in rhinorrhoea (XXII) 
with a combination of L. acidophilus NCFM and B. lactis 
Bi-07. The reduction and cough and fever could also be 
observed after administration of a commercial product 
containing L. acidophilus and B. bifidum (Rerksuppaphol 
and Rerksuppaphol, 2010). Sur et al. (2011) demonstrated 
a significant reduction in diarrhoea (VII) after L. casei 
Shirota administration (P=0.01), whereas administration of 
L. rhamnosus GG induced significantly less URTIs (Hojsak 
et al., 2010a,b). Significant lower dysentery, pneumonia 
episodes and lower respiratory tract infections were 
observed in the treatment group that received B. lactis 
HN019 (Sazawal et al., 2010). Only one intervention in the 
healthy population evaluating the effects of calcium and 
probiotics on the incidence and duration of acute diarrhoea 
and acute respiratory tract infections indicated increased 
complications after daily supplementation of 0.5×109 cfu 
L. reuteri DSM17938 (Agustina et al., 2012). In this study, 
healthy 1-6 year old children from low socioeconomic 
communities reported a significant change in bowel habits 
(less regular defecation) compared to the ‘L. casei’ and the 
‘calcium’ groups. In addition, three children developed 
asthma in the reuteri group. Although significant, this 
data was based on very few cases. Furthermore, the study 
by Francavilla et al. (2012) did not observe any of these 
AEs during administration of L. reuteri DSM17938. Both 
Tolone et al. (2012) and Hurduc et al. (2009) documented 
significant less AEs in treatment group compared to the 
control group in H. pylori infected children. Perhaps of 
more interest, is that there was no significantly higher 
occurrence rate of AEs in the treatment group in immune 
compromised children. On the contrary, significantly less 
AEs were observed compared to the control arm (Hojsak 
et al., 2010a,b; Kumar et al., 2013; Wada et al., 2010). These 
promising results indicate that the current administered 
probiotics can be safely evaluated in immune compromised 
children, and thereby pave the way for further exploration 
of the therapeutic potential of probiotics and synbiotics, or 
at least decrease complications and comorbidity.
Overall, none of the serious AEs were considered related 
to the probiotic product. None of the reported events of 
infection, bacteraemia or sepsis were associated with the 
administered probiotics, and no probiotic species were 
positively cultured from an infection during the intervention 
and follow-up periods. As probiotics are living organisms, 
they have the potential to induce systemic infections, 
adjuvant side-effects, cause immunomodulation, are able to 
transfer genes and can possess harmful metabolic activities 
(Salminen et al., 1998). Systemic infections due to lactic acid 
bacteria (LAB) occur rarely compared to other opportunistic 
bacteria (Dicks and Botes, 2010). Nevertheless, over 200 
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case reports demonstrated that Lactobacillus species are 
able to cause, and are often associated with bacteraemia and 
endocarditis (Cannon et al., 2005). Although of concern, 
only a very small portion (1.7%) was likely related to heavy 
dairy consumption, and no cases were associated with 
probiotic intake. In agreement, despite a rapid increase 
in L. rhamnosus GG intake in Finland, there has been no 
increase in Lactobacillus bacteraemia frequency observed 
since 1990 (Salminen et al., 2002). In addition, LAB have 
been safely used for many decades, since humans started 
consuming fermented milk products.
Previous case reports reported three Lactobacillus sepsis 
cases after probiotic administration of L. rhamnosus GG in 
infants with short-bowel syndrome (SBS; De Groote et al., 
2005; Kunz et al., 2004). In addition, Munakata et al. (2010) 
and Ku et al. (2006) observed D-lactic acidosis in children 
with SBS after supplementation with probiotic species. 
SBS is characterised as a reduction in functional gut mass, 
thereby being insufficient to maintain nutrient and fluids 
levels (Reddy et al., 2013). SBS is associated with increased 
intestinal permeability and bowel inflammation (Cole et al., 
2010; Reddy et al., 2013) and thus renders the individual 
more susceptible for bacterial translocation and sepsis. 
Nevertheless, the small RCT by Sentongo et al. (2008) did 
not indicate any AEs, and several previous case reports and 
case control studies in children with SBS encountered no 
health risks (Reddy et al., 2013). It is beyond the scope of 
this study to carefully investigate the isolated case reports 
on-by-one to fully understand the reason for such AEs. 
However, within the controlled framework of RCTs these 
side effects have not been reported. One should however 
bear in mind that this cross-over RCT only allocated nine 
participants (Sentongo et al., 2008). Regarding the other 
immune compromised children within this subgroup, the 
level of inflammation determines the risk of infection and 
outcome of the patient (Bengmark, 1998). Due to on-going 
systemic inflammation, these children are more susceptible 
to complications, bacterial translocation and sepsis (Alverdy 
et al., 2003). Increased surveillance thus remains essential 
when evaluating probiotics in this susceptible population.
Despite a substantial number of participants with an 
intestinal disorder were included in the analysis (n=2,960), 
only 50 AEs were documented. Similar results were 
observed in participants with an inflammatory disorder 
or allergy; 1,109 participants reported a total of 94 AEs. 
The participants in these subgroups received a wide range 
of dosages, whereas some participants received a very 
high dosage of 1.5×1011 cfu of L. acidophilus L-92 per day 
with no significant difference in AEs (Torii et al., 2011). 
These data further underpin the safety of this strain in 
children. In all patient subgroups probiotic strains were 
evaluated exceeding 1.0×1010 cfu/day. Although promising, 
preferably all strains should be tested at very high dosages 
in each patient population to establish an optimal dosage-
response relation in children. In addition, a higher exposure 
of probiotic organisms could be associated with a higher 
risk or incidence of AEs. The exposure duration was overall 
less than three months and there was a lack of available 
long-term follow-up studies; the safety profile of chronic 
probiotic exposure in children thus remains undetermined. 
Although currently long-term probiotic administration 
(Hatakka et al., 2001; Saavedra et al., 2004) and long-term 
effects after administration (up to 10 years) do not seem 
to be associated with adverse health risks (Kalliomäki et 
al., 2003; Luoto et al., 2010), these data are limited. More 
focus on long-term effect evaluation is essential in future 
study designs.
Analysis of the 74 papers identified a serious lack of 
proper documentation of the intervention as well as safety. 
Data is less valuable since 42% of the applied probiotics 
lacked a specific strain designation, and even a case were 
no genus or species was provided. Since properties of 
specific strains cannot be generalised, it is not possible 
to associate the efficacy and safety data to all probiotics. 
In addition, incomplete documentation of applied dosage 
impairs a proper analysis. Future research with data from 
these studies should thus be cross-checked and possibly 
reclassified. In addition, taxonomy of the probiotic 
organisms occasionally seems peculiar (e.g. Saccharomyces 
thermophilus). Proper strain identification by PCR can 
provide a definite answer which organism is applied to the 
participants. Regarding the safety, 28% of the studies solely 
focussed on efficacy rather than taking safety into account; 
these studies did not discuss AEs or the safety aspects of 
the intervention in any kind. The poor documentation is 
likely to be attributable to the large portion of commercial 
available products that were supplemented (52.6%). 
Investigators probably rely on previous reported safety 
data and specific product formulation (e.g. strain and cfu) 
is in these cases often undisclosed.
The majority of the studies did not provide any AEs or 
only described uncommon reported AEs and thereby 
did not quantify or discuss the common AEs such as 
diarrhoea, flatulence or nausea. This likely led to an 
underrepresentation of several CTCAE categories and 
could affect overall conclusions. Incidences of serious 
AEs are often poor described and AEs are designated as 
unrelated to the study product, whilst large meta-analyses 
can provide new insights in the correlation between AEs 
and probiotic products.
The efficacy is essential for a proper risk-benefit analysis, 
and the ratio between AEs and documented beneficial effects 
is thus essential safety evaluation. If the potential beneficial 
therapeutic effects of a probiotic or synbiotic product 
outweigh the associated adverse health effects, it may justify 
the use of the product. This study, however, did not focus 
on the efficacy but solely on safety, although a reduction in 
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the incidence and duration of diarrhoea was often observed. 
This study did not stratify for the formulation or commercial 
availability of the probiotic products. Whether a single 
probiotic, a probiotic mixture or synbiotic product is more 
efficacious remains to be determined.
A clear general safety conclusion is nearly impossible due 
to the inconsistent and imprecise AE documentation in 
combination with the vast variety in supplemented strains, 
dosages, administration regimes, target populations and 
outcomes. Very few studies address specifically probiotic 
complications and are not designed to assess the safety 
profile. Additionally, safety should be evaluated on a strain-
by-strain basis, depending on long-term and high dosage 
exposure. Based on the study by Hempel et al. (2011) 
combined with the current data, we still cannot provide 
a decisive safety profile of probiotics and synbiotics in 
children, however, based on data from controlled clinical 
trials, probiotics and synbiotics seem to be safe in children 
between 0 and 18 years. In addition, with respect to the 
previous safety studies in immune compromised adults and 
very young infants (Van den Nieuwboer et al., 2014, 2015) 
we argue that probiotic and synbiotic administration in a 
controlled setting of a RCT is safe, even in the vulnerable 
population. Therefore we urge investigators to further 
explore the potential of probiotics while at the same time 
designing properly powered and controlled clinical trials 
with standardised AE reporting.
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